<DOC>
	<DOC>NCT00948246</DOC>
	<brief_summary>The purpose of this study is to collect additional safety, performance and effectiveness data of the Easyband gastric band medical device in the treatment of morbid obesity in 4 European countries where the device is a CE marked approved product.</brief_summary>
	<brief_title>European Union (EU) Post-Market Study on Easyband®</brief_title>
	<detailed_description />
	<mesh_term>Obesity, Morbid</mesh_term>
	<criteria>Demonstrated failure in losing weight with noninvasive therapies BMI ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 and &lt; 40 kg/m2 with one or more significant medical conditions related to obesity patients with BMI greater than 60 kg/m2 patients who are not indicated for laparoscopic bariatric surgery patients with known allergies to implant materials such as silicone and PEEK patients whose abdominal structures have been damaged during preceding surgical procedures pregnant women patients under the age of 18 years patients treated with steroids patients addicted to alcohol or drugs, or who are mentally unstable, or who may not comply with the followup and dietary restrictions patients already implanted with a device sensitive to radiofrequency emissions such as implanted pacemaker, defibrillators, cochlear implants, implantable pumps etc</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
</DOC>